BUSINESS
Pfizer Japan Files 20-Valent Pneumococcal Jab for Older Adults, High-Risk People
Pfizer said on September 13 that it has filed its 20-valent pneumococcal conjugate vaccine in Japan for the prevention of pneumococcal infection in older adults and individuals at a high risk of contracting an infectious disease caused by pneumococcus. The…
To read the full story
Related Article
BUSINESS
- Astellas Cuts Costs Ahead of Schedule, Key Assets Entering Late Stages
February 5, 2026
- Astellas Lifts Full-Year Forecast, Drops 2 Pipeline Programs
February 5, 2026
- 3D Says Toho Share Purchase Is Long-Term Investment, Not Attempt at Control
February 5, 2026
- MSA Drug NPC-29 Set to Enter PIII This Month: Nobelpharma CEO
February 5, 2026
- Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
February 4, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





